Dr Reddy's Laboratories Ltd（RDY）股票分析RDYDr Reddy's Laboratories Ltd

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Dr. Reddy's Laboratories Ltd is a good buy right now due to its current price of $13.21 being below the analyst price target of $14.80, indicating a potential upside of 11.99%. Additionally, the stock's RSI is at 72.641, suggesting it is nearing overbought territory but still has momentum. The forward P/E ratio is 27.027, which is reasonable given the company's growth potential, especially with the recent launch of its generic Sugammadex injection expected to increase market share significantly. However, a key risk is the declining gross margin, which fell to 44.82% in the latest quarter, indicating potential pressure on profitability.

1 analysts cover RDY: 0 rate it Buy, 0 Hold and 1 Sell.